|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on May 24, 2002; DOI 10.1182/blood-2002-02-0376.
NEOPLASIA
From the Department of Adult Oncology, Dana-Farber
Cancer Institute, Harvard Medical School, Boston, MA.
2-Methoxyestradiol (2ME2) an estrogen derivative, induces growth
arrest and apoptosis in leukemic cells and is also antiangiogenic. In
this study, we demonstrate that 2ME2 inhibits growth and induces apoptosis in multiple myeloma (MM) cell lines and patient cells. Significantly, 2ME2 also inhibits growth and induces apoptosis in MM
cells resistant to conventional therapies including melphalan (LR-5),
doxorubicin (Dox-40 and Dox-6), and dexamethasone (MM.1R). In contrast
to its effects on MM cells, 2ME2 does not reduce the survival of normal
peripheral blood lymphocytes. Moreover, 2ME2 enhances Dex-induced
apoptosis, and its effect is not blocked by interleukin-6 (IL-6). We
next examined the effect of 2ME2 on MM cells in the bone marrow (BM)
milieu. 2ME2 decreases survival of BM stromal cells (BMSCs), as well as
secretion of vascular endothelial growth factor (VEGF), and IL-6
triggered by the adhesion of MM cells to BMSCs. We show that apoptosis
induced by 2ME2 is mediated by the release of mitochondrial
cytochrome-c (cyto-c) and Smac, followed by the activation of
caspases-8, -9, and -3. Finally, 2ME2 inhibits MM cell growth, prolongs
survival, and decreases angiogenesis in a murine model. These studies,
therefore, demonstrate that 2ME2 mediates anti-MM activity directly on
MM cells and in the BM microenvironment. They provide a framework for
the use of 2ME2, either alone or in combination with Dex, to overcome
drug resistance and to improve outcome in MM.
(Blood. 2002;100:2187-2194) 2-Methoxyestradiol (2ME2) a natural metabolite of
estradiol, is a potent antitumor and antiangiogenic agent in leukemic
cells.1-7 Although 2ME2 has potent antiproliferative
activity in various tumorigenic and nontumorigenic cell lines, the
mechanisms mediating the biologic effects of 2ME2 remain unclear. We
and others8-11 have demonstrated that multiple myeloma
(MM) cells express estrogen receptors (ERs) and that antiestrogen
compounds, such as tamoxifen and ICI 182 780, induce apoptosis in MM
cells. Treatment of MM cells with estrogen (E2) alone did not alter the
growth of MM cells.9 Moreover, despite its being a natural
derivative of estradiol (E2), 2ME2 binds poorly to the ERs; therefore,
the antiproliferative effects of 2ME2 are not mediated by
ERs.12,13 These findings, coupled with our studies,
suggest that 2ME2-mediated effects on MM cells are independent of ER.
Previous studies using xenografts and metastatic disease models in mice
have suggested that 2ME2 targets not only the tumor cell but also the
tumor vasculature.2,14 Recent reports of increased bone
marrow (BM) angiogenesis in multiple myeloma (MM),15-17 coupled with the known antiangiogenic properties of
2ME2,2,14 provide a potential rationale for evaluating
2ME2 as a novel therapeutic in MM.
In the present study, we characterize the in vitro effects of 2ME2
against MM cells in the BM microenvironment and its in vivo anti-MM
activity in an animal model. We demonstrate that 2ME2 induces apoptosis
in MM cells resistant to conventional therapies, and we delineate the
signaling cascades mediating its anti-MM activity. Significantly, we
show that 2ME2 directly decreases cytokine secretion in bone marrow
stromal cells (BMSCs), thereby modulating the tumor BM environment.
These data, along with our demonstration of its anti-MM and
antiangiogenesis effects in vivo, provide the framework for clinical
trials of 2ME2 to improve patient outcome in MM.
Cell culture and reagents
Proliferation assays
MTT assays Cell viability was assessed by 3-(4,5-dimethylthiozol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Chemicon International, Temecula, CA) assay according to the manufacturer's instructions (Roche Molecular Biochemical), with some modifications. Cells were seeded in 96-well plates in RPMI 1640 medium containing 5% FBS. 2ME2 or Dex was added 24 hours later and incubated for 72 hours. Cell viability was evaluated as previously described.21,22Enzyme linked immunosorbent assays Conditioned media were generated from 24-hour cultures of MM patient-derived BMSCs, MM.1S cells, and BMSCs + MM.1S cells, either untreated or treated with 3 µM 2ME2; IL-6 and VEGF levels were measured using enzyme-linked immunosorbent assay (ELISA; R&D Systems, Minneapolis, MN), as previously described.23 BMSC viability at 24 hours was greater than 80%, as determined by trypan blue exclusion assay. Briefly, 96-well plates were coated with either anti-human VEGF or IL-6 antibodies overnight, washed, and then blocked with 300 µL phosphate-buffered saline (PBS), 1% bovine serum albumin (BSA), 5% sucrose, and 0.05% NaN3 for 2 hours. After washing, 100 µL sample or standards diluted in Tris-Cl, 0.1% BSA, and 0.05% Tween 20 (pH 7.3) was added to the wells and incubated for 2 hours at room temperature. The cells were rinsed, and either biotinylated anti-human VEGF or IL-6 antibodies were added for 2 hours at room temperature. After a further washing step, the wells were incubated with streptavidin-horseradish peroxidase for 20 minutes at room temperature and rinsed. The reaction was started by the addition of 100 µL H2O2 and tetramethylbenzidine for 30 minutes at room temperature. After stopping the reaction with 1 µM H2SO4, the optical density of each well was detected by means of a microtiter plate reader at 450 nm, with correction at 540 nm.Western blotting Total cell lysates and cytosolic extracts were prepared as previously described.24 Briefly, equal amounts of proteins were resolved by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membranes. Proteins were then transferred to nitrocellulose filters, blocked by incubation in 5% dry milk in PBST (0.05% Tween-20 in PBS), and probed with anti-cyto-c, anti-Smac (kindly provided by Dr Xiaodong Wang, University of Texas Southwestern Medical Center, Dallas), anti-caspase-3 (Santa Cruz, CA), anti-caspase-8 and -9 (Transduction Laboratories, Detroit, MI), or anti-SHP2 (Santa Cruz, CA) antibodies. Blots were then developed by enhanced chemiluminescence (ECL; Amersham, Arlington Heights, IL). Preparation of cell lysates for PARP immunoblot analysis was performed as described using C-2-10 anti-PARP monoclonal antibody.25Quantification of apoptosis Dual fluorescence staining with DNA-binding fluorochrome Hoechst 33342 (HO) and propidium iodide (PI) was used to quantitate the percentage of apoptotic (PI HO+) cells using
flow cytometry (Vantage; Becton Dickinson), as previously described.26 DNA fragmentation assays were also performed,
as in prior studies.27
Preparation of S-100 cytosolic fractions from MM.1S cells MM.1S MM cells were washed twice with PBS, and the pellet was suspended in 5 ml ice-cold buffer A (20 mM HEPES [N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid], pH 7.5, 1.5 mM MgCl2, 10 mM KCl, 1 mM EDTA [ethylenediaminetetraacetic acid], 1 mM EGTA [ethyleneglycotetraacetic acid], 1 mM dithiothreitol, 0.1 mM phenylmethylsulfonyl fluoride, 10 µg/mL leupeptin and aprotinin and pepstatin A) containing 250 nM sucrose. Cells were homogenized by douncing 3 times in a Dounce homogenizer with a sandpaper-polished pestle. Cytosolic fractions were isolated as previously described.24 Immunoblots were scanned using an LKB producer (Bromma, Sweden) Ultrascan XL laser densitometer and analyzed with the Gelscan software package. Signal intensity was determined in a linear range and normalized to that for SHP2.Drug preparation and in vivo evaluation in murine tumor model For animal studies, 2ME2 was kindly provided by Entremed (Rockville, MD). 2ME2 (100 mg/kg) was suspended in 0.5% carboxymethylcellulose (Sigma). Six-week-old triple immune-deficient beige nude xid (BNX) mice were obtained from Frederick Cancer Research and Development Center (Frederick, MD). All animal studies were conducted according to protocols approved by the Animal Ethics Committee of the Dana Farber Cancer Institute. Mice were observed daily for signs of toxicity. Terminal bleeding was performed under anesthesia using isoflurane inhalation, and animals were killed by CO2 asphyxiation.To determine the in vivo anti-MM activity of 2ME2, mice were inoculated subcutaneously in the flank with 3 × 107 RPMI 8226 MM cells in 100 µL RPMI 1640 medium, together with 100 µL Matrigel (Becton Dickinson, Bedford, MA). Drug treatment was started after the development of measurable tumor. The drug (100 mg/kg) was given daily using an orogastric feeding tube, with carboxymethylcellulose 0.5% as a control. Serial caliper measurements of perpendicular diameters were taken every other day to calculate tumor volume using the following formula: 4/24 × (shortest diameter)2 × (longest diameter). Animals were killed if the tumor was 2 cm or larger or it was necrotic. Tumor was then harvested for hematoxylin and eosin staining and microvessel density (MVD) evaluation. For tumor growth studies, 10 mice were used in each group. CD31 immunostaining Tumor tissues were fixed in 10% neutral buffered formalin and embedded in paraffin, according to standard histologic procedures. After deparaffinization, tissue sections were pretreated with proteinase K (Roche Molecular Biochemical) at 37°C for 30 minutes before staining with rat anti-mouse CD-31 antibody (PharMingen, San Diego, CA). Positive staining was detected using secondary biotinylated rabbit anti-rat antibody, followed by incubation with streptavidin-horseradish peroxidase (DAKO, Carpenteria, CA). 3-Amino-9-ethylene carbazole (DAKO) was used as the chromogenic substrate, and sections were counterstained with Gill hematoxylin (Fisher Scientific, Fair Lawn, NJ). MVD was determined by light microscopy, as previously described.28 MVD assessment was conducted without knowledge of mouse treatment history. Areas of most intense neovascularization were counted at high magnification (× 400), and 2 investigators using double-headed light microscopy analyzed at least 5 separate fields. The mean MVD was compared among the treatment groups and analyzed using the Student t test.Statistical analysis Nonparametric tests and mixed models were used to analyze the data. These included the Wilcoxon signed rank test to compare proliferation in untreated and treated patient cells and the Jonchkeere-Terpstra (J-T) trend test for assessing the viability of MM cell lines resistant to conventional therapy and of healthy donors. The mixed model was used to adjust for repeated measures in the analysis of the 2ME2 patient MM-derived BMSCs. Analysis of in vivo data included a Wilcoxon rank-sum test on the change in the tumor volume and a log-rank test to compare the overall survival.
2ME2 induces apoptosis in MM.1S cells To examine whether 2ME2 induces apoptosis in the MM.1S MM cell line, we performed DNA fragmentation and flow cytometric analyses. MM.1S MM cells were cultured in the presence or absence of 2ME2 (3 µM) for 24 and 48 hours. DNA cleavage was analyzed by agarose gel electrophoresis of the 32P-ATP labeled genomic DNA
(Figure 1A, left panel). Low to
undetectable DNA cleavage was observed in the untreated cells; in
contrast, 2ME2 induced significant cleavage of DNA into
oligonucleosomal fragments of approximately 200 base pairs. This
pattern was more pronounced following treatment with 2ME2 at 48 hours.
The finding that 2ME2 induces fragmentation of DNA into multiples of
nucleosome-sized fragments confirms changes in chromatin structure
observed during apoptosis or programmed cell death.29
Apoptosis induced by 2ME2 was further confirmed by flow cytometric
analysis using dual PI and Hoechst staining. Treatment of cells with
2ME2 (3 µM) significantly (P < .005) increased the
percentage of apoptotic cells (Figure 1A, right panel).
Effect of 2ME2 on MM cells resistant to conventional therapy Cytotoxic effects of 2ME2 on various MM cell lines, including cell lines resistant to conventional therapy (RPMI 8226, Dox-40, Dox-6, LR5, and MM.1R) was determined using an MTT assay, in the presence or absence of drug at various concentrations (0.5 µM, 1 µM, 3 µM, 10 µM, and 20 µM.). 2ME2 induced a significant (P < .0001) decrease in cell viability in a dose-dependent manner for all cell lines (Figure 1B). A 50% decrease in viable cells was noted at 1 to 3 µM of 2ME2 in most of the cell lines. IC50 of 2ME2 for LR-5 cells was 0.5 to 1.0 µM. We next examined the effect of 2ME2 on apoptosis in these cells. PI staining demonstrated a dose-dependent increase in the percentage of apoptotic (sub-G1) cells in response to 2ME2 (P < .001); however, estrogen (E2) alone did not induce apoptosis in these cells (data not shown). This finding is consistent with our prior study9 showing that exposure to E2 does not affect growth kinetics or induce apoptosis of these cells.Effect of 2ME2 on normal lymphocytes Normal lymphocytes from 5 healthy donors were also treated with various doses (0.5 µM, 1.0 µM, 3.0 µM, 10 µM, and 20 µM) of 2ME2 and were analyzed for the inhibition of proliferation and apoptosis by BrdU and PI staining, respectively. In contrast to MM cells, survival of normal lymphocytes from 5 healthy donors was not altered significantly (P = .23 from the J-T trend test), even at higher doses (3-20 µM) of 2ME2 (Figure 1C). Moreover, no significant (P = .31) apoptosis of normal lymphocytes was observed in response to 2ME2 (data not shown). Taken together, these findings indicate that 2ME2 has selective anti-MM activity.Effect of 2ME2 on patient MM cells We next determined the effects of 2ME2 on MM cells freshly isolated from patients who had relapsed after multiple prior therapies, including therapy with dexamethasone, melphalan, or thalidomide. Tumor cells were purified from bone marrow aspirates by CD138+ selection using CD138 (Syndecan-1) Micro Beads and Auto MACS magnetic cell sorting. Treatment of MM cells from 5 patients (patients 1-5) with 2ME2 (9 µM) significantly (P = .06) decreased growth, as measured by BrdU incorporation (Figure 1D). To further determine whether growth inhibition correlates with apoptosis in patient MM cells, we next determined the effects of 2ME2 (9 µM) on poly (ADP-ribose) polymerase (PARP) cleavage, a known signature event during apoptosis.30,31 2ME2 (9 µM) induced PARP cleavage in patient MM cells, consistent with apoptosis, but failed to induce PARP cleavage in normal lymphocytes (Figure 1E). These findings correlate with our earlier results (Figure 1C) and another study32 demonstrating lack of cytotoxicity of 2ME2 (9 µM) on normal lymphocytes. Taken together, our results suggest that 2ME2 inhibits growth and induces apoptosis in patient MM cells.Effect of 2ME2 on patient MM-derived bone marrow stromal cells In MM, tumor cells are predominantly localized in the BM microenvironment because of their adherence to extracellular matrix proteins and to BMSCs. This interaction between MM cells and BMSCs triggers the production of cytokines mediating autocrine and paracrine growth and survival of MM cells and protection against drug-induced apoptosis.33 Therefore, we next examined the effect of 2ME2 on patient MM-derived BMSCs from 5 MM patients. Treatment of BMSCs with 2ME2 significantly (slope = 5.5; P = .002)
decreases viability (Figures
2A,
patients A-C). To determine whether 2ME2-induced growth inhibition
correlates with apoptosis in patient BMSCs, we next examined the
effects of 2ME2 (9 µM) on PARP cleavage. 2ME2 (3 µM) induced PARP
cleavage, consistent with apoptosis (Figure 2B, patient A and B). Taken
together, these results suggest that 2ME2 not only acts directly on MM
cells, but also affects the BM microenvironment.
Effect of 2ME2 on IL-6 secretion in BMSCs Adhesion of MM cells to BMSCs triggered the secretion of factors such as IL-6 from BMSCs, which regulate the growth of MM cells in an autocrine or a paracrine manner.34 To determine whether 2ME2 also affected the secretion of IL-6, we next examined the effect of 2ME2 on IL-6 production in the BM microenvironment. As seen in Figure 2C, 2ME2 significantly (P < .005) inhibited IL-6 secretion in MM patient BMSCs triggered by MM cell adhesion. Reports that high serum levels of IL-6 contribute to clinical chemoresistance and treatment failure,35 coupled with our demonstration that 2ME2 decreases MM adhesion-induced IL-6 secretion from BMSCs, suggest that 2ME2 may overcome drug resistance in patients with advanced MM.Effect of Dex and IL-6 on response of MM cells to 2ME2 To determine whether the effects of 2ME2 are additive with conventional therapies, we next examined whether Dex (0.0005-0.5 µM) enhanced 2ME2 (3 µM) effects on proliferation of Dex-sensitive (MM.1S) MM cells. As seen in Figure 3A, the combination of 2ME2 and Dex induces more growth inhibition than the treatment of MM.1S cells with 2ME2 alone. Dex (0.05 µM) and 2ME2 (3 µM) increased growth inhibition by 30% relative to cultures with 2ME2 alone (P = .05, one-sided Wilcoxon rank-sum test). PI staining after Dex (0.05 µM) and 2ME2 (3 µM) revealed 93% ± 6.1% apoptosis versus 66% ± 4.3% cell death induced by Dex alone.
We and others36-39 have shown that IL-6 protects against Dex-induced apoptosis; hence we next examined the effect of IL-6 on 2ME2-induced apoptosis. MM.1S cells were treated with 2ME2 (3 µM) or Dex (0.05 µM), in the presence and absence of IL-6 (10 ng/mL). As seen in Figure 3B, the median viability was 41% for Dex and 78% for Dex + IL-6 (P = .05, as determined by one-sided Wilcoxon rank-sum test), whereas for 2ME2 the median viability was 45% with 2ME2 alone and 48% with 2ME2 + IL-6 (P = .20, Wilcoxon test, as above). These findings suggest that IL-6 failed to abrogate the effects of 2ME2 on MM.1S cells. In contrast, and as in our prior studies,38 IL-6 blocked Dex-induced decreases in MM.1S cell viability. Taken together, our data suggest that 2ME2 overcomes the growth and protective effects of IL-6 on MM cells, and they indicate distinct mechanisms of action for 2ME2 and Dex against MM cells. 2ME2 induces mitochondrial release of cytochrome-c and Smac Having shown the biologic sequelae of 2ME2 in MM cells, we next examined the signaling mechanisms mediating apoptosis triggered by 2ME2. Our prior studies have characterized Dex-induced apoptotic mechanisms in MM.1S MM cells, and we therefore studied 2ME2 effects using these cells to compare differential signaling cascades triggered by Dex versus 2ME2. Previous studies have shown that 2ME2-induced apoptosis involves mitochondrial damage.32 We first determined whether treatment of MM.1S cells is associated with the release of mitochondrial apoptogenic proteins, cyto-c and Smac. Our recent studies have demonstrated that Smac, but not cyto-c, is released from mitochondria into the cytosol during Dex-induced apoptosis in MM.1S cells.24,40 To determine whether 2ME2-induced apoptosis in MM.1S cells is associated with the mitochondrial release of cyto-c, Smac, or both, we treated MM.1S cells with 2ME2 for various times and analyzed cytosolic and mitochondrial extracts for levels of cyto-c and Smac. As seen in Figure 4A-B (upper panels), 2ME2 increased cyto-c and Smac levels in cytosol at 48 hours. Densitometric analysis of the immunoblot demonstrated that 2ME2 induces a 4- to 5-fold increase in cytosolic cyto-c and Smac levels compared with untreated cells (Figure 4A-B). The increase in cyto-c and Smac levels was associated with a concomitant decrease in mitochondrial Smac or cyto-c levels (data not shown). Moreover, the 2ME2-induced increases in cytosolic cyto-c or Smac levels were specific because no changes were observed in levels of cytosolic SHP2 (Figure 4A-B, lower panels). These results suggest that 2ME2-induced apoptosis is accompanied by the accumulation of Smac and cyto-c in the cytosol. In contrast, and as in our prior studies,24 Dex-induced apoptosis was associated with the mitochondrial release of Smac, but not of cyto-c (Figure 4A-B).
To determine whether 2ME2 also induces cyto-c or Smac release in other MM cell lines, we treated Dox-40, MM.1R and LR-5 MM cells with 2ME2 (3 µM) for 48 hours, followed by analysis of cytosolic extracts for levels of cyto-c and Smac. As seen in Figure 4C and 4D (upper panels), 2ME2 triggers accumulation of cyto-c and Smac levels in the cytosol of Dox-40 and LR-5 MM cells. Similar results were obtained using the MM.1R MM cell line (data not shown). 2ME2-induced increases in cytosolic cyto-c or Smac levels were specific because no changes were observed in levels of cytosolic SHP2 (Figure 4C-D, lower panels). Taken together, these results suggest that 2ME2-induced apoptosis is accompanied by the accumulation of Smac and cyto-c in the cytosol. 2ME2-induced apoptosis is mediated by activation of the caspase cascade Smac promotes caspase activation through the cyto-c/Apaf-1/caspase-9 pathway,41 and our prior study in MM cells demonstrated that Dex triggers the release of Smac from mitochondria into cytosol, with sequential activation of caspase-9 and caspase-3.40 To examine whether 2ME2-induced Smac release and apoptosis in MM cells is associated with activation of caspase-9, cytosolic extracts from 2ME2-treated MM.1S cells were subjected to immunoblot analysis using anti-caspase-9 antibody. As seen in Figure 5A, treatment of MM.1S cells with 2ME2 (3 µM) induces proteolytic cleavage of procaspase-9 into 37- and 35-kDa fragments. We also assayed for catalytic activity of caspase-9 using LEHD-pNA conjugated substrate in a colorimetric protease assay.40 Incubation of cytosolic extracts from 2ME2-treated MM.1S cells with LEHD-pNA was associated with cleavage of LEHD-pNA (data not shown). Taken together, these findings demonstrate that the treatment of MM.1S cells with 2ME2 is associated with the activation of caspase-9.
Multiple studies have shown that upstream events mediating mitochondrial cyto-c release induce sequential activation of caspase-8, cleavage of Bid, translocation of cleaved Bid from the cytoplasm into mitochondria, and release of cyto-c.42,43 Because 2ME2 induces the release of cyto-c, we next assayed for activation of caspase-8 by 2ME2. As seen in Figure 5B, 2ME2 (3 µM) also triggers proteolytic cleavage of caspase-8. In contrast, and as in our prior study,40 Dex-induced apoptosis is not associated with caspase-8 activation (Figure 5B). Previous studies have demonstrated that caspase-8 and -9 activate
downstream apoptotic caspase-3 (CPP32).44 Furthermore, in
a cell-free system, the addition of purified cyto-c to cyto-c-depleted extracts activates caspase-3 and DNA fragmentation.45
Given that treatment of MM.1S cells with 2ME2 activates caspase-8 and -9, we next determined whether caspase-3 is cleaved and activated in
response to 2ME2. MM.1S cells were treated with 2ME2 (3 µM), and cell
lysates were subjected to immunoblotting with either caspase-3 or its
known substrate, PKC Collectively, comparative analyses of 2ME2 and Dex-induced apoptotic signaling cascades suggest that 2ME2, in contrast to Dex, triggers multiple signaling pathways (Figure 5D). For example, 2ME2 induces the release of cyto-c and Smac, whereas Dex triggers the release of only Smac; 2ME2 activates caspase-8 and -9, whereas Dex triggers activation of only caspase-9; and finally, IL-6 protects against Dex-, but not 2ME2-induced apoptosis. Because 2ME2 triggers apoptosis in Dex-resistant MM cells, elucidating the 2ME2-induced apoptotic signaling pathways may identify additional apoptotic targets and delineate abnormalities in signaling pathways that confer Dex resistance. 2ME2 suppresses in vivo tumor growth in SCID mouse model Having shown the signaling mechanisms mediating the anti-MM effects of 2ME2 in vitro, we next determined whether these in vitro effects correlate with the in vivo activity of 2ME2 using our SCID mouse model. Immune-deficient beige-nude-xid (BNX) mice were inoculated subcutaneously in the flank with 3 × 107 RPMI 8226 MM cells in 100 µL RPMI 1640 medium, together with 100 µL Matrigel. Daily oral administration of 2ME2 (100 mg/kg) starting after the development of measurable tumor significantly reduced MM tumor growth (35%-40%; P < .05) (Figure 6A) and increased survival (Figure 6B) compared with the control group treated with vehicle (Matrigel) only. No significant toxicity, as evidenced by lack of weight changes, was observed in any treatment groups. These findings suggest that 2ME2 at molar concentrations is effective in controlling the growth of human MM in mice. Other in vivo preclinical studies have shown that 2ME2 is also effective in reducing tumor burden in Meth-A sarcoma or B16 melanoma, in non-estrogen-dependent human breast carcinoma (MDA-MB-435), and in human pancreatic (MIA PaCa-2) xenograft mouse models.2,14
Because 2ME2 is a known antiangiogenic agent and recent reports show increased BM angiogenesis in MM,15-17 we examined the effect of 2ME2 on intratumoral microvessel density (MVD), evidenced by CD-31 immunostaining of human MM tumors in mice. A significant decrease in MVD was noted in 2ME2-treated animals (Figure 6D) versus the cohort treated with control vehicle alone (Figure 6C). The number of CD-31+ blood vessels per low-power (400 ×) field was 10.30 ± 1.0 in 2ME2-treated versus 19.10 ± 1.9 in control groups (P < .05) (Figure 6E). Taken together, these studies demonstrate that 2ME2 is effective in inhibiting tumor cell growth and angiogenesis in MM. Having shown the in vivo effects of 2ME2 on angiogenesis, we determined whether 2ME2 altered VEGF secretion in the BM microenvironment. 2ME2 induces a significant (P < .05) decrease in VEGF secretion in MM.1S cells (34% ± 2.1% decrease, n = 3) and in BMSCs (41% ± 3.2% decrease, n = 3). Our results are consistent with other studies suggesting that VEGF expression, as evaluated by immunohistochemical analysis, is down-regulated concomitantly with tumor angiogenic suppression.46 Because we and others16,17 have recently demonstrated that VEGF is an angiogenic factor and a trigger of growth and migration in MM cells, our present findings suggest an additional mechanism whereby 2ME2 mediates anti-MM activity. Our study, therefore, demonstrates that 2ME2 can directly induce apoptosis in MM cells and act in the BM microenvironment to decrease cytokines mediating tumor cell growth survival and angiogenesis. These studies provide the framework for clinical trials of 2ME2 to overcome drug resistance and improve patient outcome in MM.
We thank Dr Xiaodong Wang for providing Smac-related reagents. We also thank Kamal Chauhan for technical assistance.
Submitted February 5, 2002; accepted May 2, 2002.
Prepublished online as Blood First Edition Paper, May 24, 2002; DOI 10.1182/blood-2002-02-0376.
Supported by National Institutes of Health grants R0-1 50947 and PO-1 78378, Multiple Myeloma Research Foundation Senior Research Awards (D.C., T.H.), International Myeloma Foundation Fellow Award (K.P.), and Doris Duke Distinguished Clinical Research Scientist Award (K.C.A.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Kenneth C. Anderson, Dana-Farber Cancer Institute, 44 Binney St, Boston, MA 02215; e-mail: kenneth_anderson{at}dfci.harvard.edu.
1. Cushman M, He H-M, Katzenellenbogen J-A, Lin C-M, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem. 1995;38:2041-2049[CrossRef][Medline] [Order article via Infotrieve].
2.
Klauber N, Parangi S, Flynn E, Hamel E, D'Amato R-J.
Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol.
Cancer Res.
1997;57:81-86
3.
Lottering M-L, Haag M, Seegers J-C.
Effects of 17 beta-estradiol metabolites on cell cycle events in MCF-7 cells.
Cancer Res.
1992;52:5926-5932
4.
D'Amato R-J, Lin C-M, Flynn E, Folkman J, Hamel E.
2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site.
Proc Natl Acad Sci U S A.
1994;91:3964-3968 5. Mukhopadhyay T, Roth JA. Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. Oncogene. 1997;14:379-384[CrossRef][Medline] [Order article via Infotrieve]. 6. Schumacher G, Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J Cancer Res Clin Oncol. 2001;127:405-410[CrossRef][Medline] [Order article via Infotrieve]. 7. Kumar A-P, Garcia G-E, Slaga T-J. 2methoxyestradiol blocks cell-cycle progression at G(2)/M phase and inhibits growth of human prostate cancer cells. Mol Carcinog. 2001;31:111-124[CrossRef][Medline] [Order article via Infotrieve]. 8. Danel L, Vincent C, Rousset F, et al. Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas. J Steroid Biochem. 1988;30:363-367[CrossRef][Medline] [Order article via Infotrieve].
9.
Treon SP, Teoh G, Urashima M, et al.
Anti-estrogens induce apoptosis of multiple myeloma cells.
Blood.
1998;92:1749-1757
10.
Otsuki T, Yamada O, Kurebayashi J, et al.
Estrogen receptors in human myeloma cells.
Cancer Res.
2000;60:1434-1441
11.
Wang L-H, Yang X-Y, Mihalic K, Xiao W, Li D, Farrar W-L.
Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3.
J Biol Chem.
2001;276:31839-31844 12. Maran A, Zhang M, Kennedy AM, et al. 2-Methoxyestradiol induces interferon gene expression and apoptosis in osteosarcoma cells. Bone. 2002;30:393-398[Medline] [Order article via Infotrieve]. 13. Merriam G-R, MacLusky N-J, Picard M-K, Naftolin F. Comparative properties of the catechol estrogens, I: methylation by catechol-O-methyltransferase and binding to cytosol estrogen receptors. Steroids. 1980;36:1-11[CrossRef][Medline] [Order article via Infotrieve]. 14. Fotsis T, Zhang Y, Pepper MS, et al. The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth. Nature. 1994;368:237-239[CrossRef][Medline] [Order article via Infotrieve]. 15. Ribatti D, Vacca A, Nico B, et al. Bone marrow angiogenesis and mast cell density increase simultaneously with progression of human multiple myeloma. Br J Cancer. 1999;79:451-455[CrossRef][Medline] [Order article via Infotrieve].
16.
Podar K, Tai YT, Davies FE, et al.
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.
Blood.
2001;98:428-435
17.
Vacca A, Ribatti D, Presta M, et al.
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Blood.
1999;93:3064-3073
18.
Moalli P-A, Pillay S, Weiner D, Leikin R, Rosen S-T.
A mechanism of resistance to glucocorticoids in multiple myeloma: transient expression of a truncated glucocorticoid receptor mRNA.
Blood.
1992;79:213-222
19.
Damiano J-S, Cress A-E, Hazlehurst L-A, Shtil A-A, Dalton W-S.
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines.
Blood.
1999;93:1658-1667
20.
Maeshima Y, Manfredi M, Reimer C, et al.
Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin.
J Biol Chem.
2001;276:15240-15248
21.
Chauhan D, Uchiyama H, Akbarali Y, et al.
Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B.
Blood.
1996;87:1104-1112
22.
Hideshima T, Chauhan D, Shima Y, et al.
Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood.
2000;96:2943-2950 23. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961[Medline] [Order article via Infotrieve].
24.
Chauhan D, Pandey P, Ogata A, et al.
Cytochrome-c dependent and independent induction of apoptosis in multiple myeloma cells.
J Biol Chem.
1997;272:29995-29997 25. Desnoyers S, Shah G-M, Brochu G, Poirier G-G. Erasable blot of poly(ADP-ribose) polymerase. Anal Biochem. 1994;218:470-473[CrossRef][Medline] [Order article via Infotrieve]. 26. Chauhan D, Hideshima T, Pandey P, et al. RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells. Oncogene. 1999;18:6733-6740[CrossRef][Medline] [Order article via Infotrieve].
27.
Chauhan D, Pandey P, Hideshima T, et al.
SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.
J Biol Chem.
2000;275:27845-27850 28. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis: correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8[Abstract]. 29. Wyllie A-H. Chromatin cleavage in apoptosis: association with condensed chromatin morphology and dependence on macromolecular synthesis. J Pathol. 1984;142:66-77. 30. Lazebnik Y-A, Kaufmann S-H, Desnoyers S, Poirier G-G, Earnshaw W-C. Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature. 1994;371:346-347[CrossRef][Medline] [Order article via Infotrieve].
31.
Aoufouchi S, Yelamos J, Milstein C.
Inhibition of apoptosis of a PARP( 32. Huang P, Feng L, Oldham E-A, Keating M-J, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature. 2000;407:390-395[CrossRef][Medline] [Order article via Infotrieve]. 33. Anderson K-C. Targeted therapy for multiple myeloma. Semin Hematol. 2001;38:286-294[CrossRef][Medline] [Order article via Infotrieve]. 34. Anderson K-C. Novel biologically based therapies for myeloma. Cancer J. 2001;7(suppl 1):S19-S23. 35. Kyrstsonis M-C, Dedoussis G, Baxevanis C, Stamatelou M, Maniatis A. Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma. Br J Haematol. 1996;92:420-422[CrossRef][Medline] [Order article via Infotrieve].
36.
Hardin J, MacLeod S, Grigorieva I, et al.
Interleukin-6 prevents dexamethasone-induced myeloma cell death.
Blood.
1994;84:3063-3070
37.
Rowley M, Liu P, Van Ness B.
Heterogeneity in therapeutic response of genetically altered myeloma cell lines to interleukin 6, dexamethasone, doxorubicin, and melphalan.
Blood.
2000;96:3175-3180
38.
Chauhan D, Kharbanda S, Ogata A, et al.
Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells.
Blood.
1997;89:227-234
39.
Chen Y-H, Desai P, Shiao R-T, Lavelle D, Haleem A, Chen J.
Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites.
Blood.
1996;87:314-323
40.
Chauhan D, Hideshima T, Rosen S, Reed J-C, Kharbanda S, Anderson K-C.
Apaf-1/cytochrome c-independent and Smac-dependent induction of apoptosis in multiple myeloma (MM) cells.
J Biol Chem.
2001;276:24453-24456 41. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33-42[CrossRef][Medline] [Order article via Infotrieve]. 42. Li H, Zhu H, Xu C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491-501[CrossRef][Medline] [Order article via Infotrieve].
43.
Kuwana T, Smith J-J, Muzio M, Dixit V, Newmeyer D-D, Kornbluth S.
Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c.
J Biol Chem.
1998;273:16589-16594 44. Chinnaiyan A-M, Dixit V-M. The cell-death machine. Curr. Biol. 1996;6:555-562[CrossRef][Medline] [Order article via Infotrieve]. 45. Liu X, Naekyung Kim C, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147-157[CrossRef][Medline] [Order article via Infotrieve]. 46. Banerjee S-K, Zoubine M-N, Sarkar D-K, Weston A-P, Shah J-H, Campbell D-R. 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis: possible role of vascular endothelial growth factor. Anticancer Res. 2000;20:2641-2645[Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  J.-M. Renoir, C. Bouclier, A. Seguin, V. Marsaud, and B. Sola Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells J. Mol. Endocrinol., March 1, 2008; 40(3): 101 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chauhan, A. Singh, M. Brahmandam, K. Podar, T. Hideshima, P. Richardson, N. Munshi, M. A. Palladino, and K. C. Anderson Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma Blood, February 1, 2008; 111(3): 1654 - 1664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. V. Rajkumar, P. G. Richardson, M. Q. Lacy, A. Dispenzieri, P. R. Greipp, T. E. Witzig, R. Schlossman, C. F. Sidor, K. C. Anderson, and M. A. Gertz Novel Therapy with 2-Methoxyestradiol for the Treatment of Relapsed and Plateau Phase Multiple Myeloma Clin. Cancer Res., October 15, 2007; 13(20): 6162 - 6167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kato, A. Sadarangani, S. Lange, M. Villalon, J. Branes, J. J Brosens, G. I Owen, and M. Cuello The oestrogen metabolite 2-methoxyoestradiol alone or in combination with tumour necrosis factor-related apoptosis-inducing ligand mediates apoptosis in cancerous but not healthy cells of the human endometrium Endocr. Relat. Cancer, June 1, 2007; 14(2): 351 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar, M. S. Raab, J. Zhang, D. McMillin, I. Breitkreutz, Y.-T. Tai, B. K. Lin, N. Munshi, T. Hideshima, D. Chauhan, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl) Blood, February 15, 2007; 109(4): 1669 - 1677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, P. Neri, M. Velankar, K. Podar, T. Hideshima, M. Fulciniti, P. Tassone, N. Raje, C. Mitsiades, N. Mitsiades, et al. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM) Blood, February 1, 2007; 109(3): 1220 - 1227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Podar, G. Tonon, M. Sattler, Y.-T. Tai, S. LeGouill, H. Yasui, K. Ishitsuka, S. Kumar, R. Kumar, L. N. Pandite, et al. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma PNAS, December 19, 2006; 103(51): 19478 - 19483. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Salama, A. B. Nasr, R. K. Dubey, and A. Al-Hendy Estrogen Metabolite 2-Methoxyestradiol Induces Apoptosis and Inhibits Cell Proliferation and Collagen Production in Rat and Human Leiomyoma Cells: A Potential Medicinal Treatment for Uterine Fibroids Reproductive Sciences, December 1, 2006; 13(8): 542 - 550. [Abstract] [PDF]
|
|
|
|
 |
|
 D. Chauhan, G. Li, K. Podar, T. Hideshima, P. Neri, D. He, N. Mitsiades, P. Richardson, Y. Chang, J. Schindler, et al. A Novel Carbohydrate-Based Therapeutic GCS-100 Overcomes Bortezomib Resistance and Enhances Dexamethasone-Induced Apoptosis in Multiple Myeloma Cells Cancer Res., September 15, 2005; 65(18): 8350 - 8358. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hideshima, D. Chauhan, P. Richardson, and K. C. Anderson Identification and Validation of Novel Therapeutic Targets for Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6345 - 6350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yasui, T. Hideshima, N. Raje, A. M. Roccaro, N. Shiraishi, S. Kumar, M. Hamasaki, K. Ishitsuka, Y.-T. Tai, K. Podar, et al. FTY720 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Drug Resistance Cancer Res., August 15, 2005; 65(16): 7478 - 7484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Yasui, T. Hideshima, M. Hamasaki, A. M. Roccaro, N. Shiraishi, S. Kumar, P. Tassone, K. Ishitsuka, N. Raje, Y.-T. Tai, et al. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma Blood, July 15, 2005; 106(2): 706 - 712. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. E. Sutherland, M. Schuliga, T. Harris, B. L. Eckhardt, R. L. Anderson, L. Quan, and A. G. Stewart 2-Methoxyestradiol Is an Estrogen Receptor Agonist That Supports Tumor Growth in Murine Xenograft Models of Breast Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1722 - 1732. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Podar and K. C. Anderson The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications Blood, February 15, 2005; 105(4): 1383 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lin, L. Catley, R. LeBlanc, C. Mitsiades, R. Burger, Y.-T. Tai, K. Podar, M. Wartmann, D. Chauhan, J. D. Griffin, et al. Patupilone (epothilone B) inhibits growth and survival of multiple myeloma cells in vitro and in vivo Blood, January 1, 2005; 105(1): 350 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Ricker, Z. Chen, X. P. Yang, V. S. Pribluda, G. M. Swartz, and C. Van Waes 2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1{alpha}, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., December 15, 2004; 10(24): 8665 - 8673. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Lens, I. Rosdahl, A. Ahlbom, B. Y. Farahmand, I. Synnerstad, B. Boeryd, and J. A. Newton Bishop Effect of Pregnancy on Survival in Women With Cutaneous Malignant Melanoma J. Clin. Oncol., November 1, 2004; 22(21): 4369 - 4375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Le Gouill, K. Podar, M. Amiot, T. Hideshima, D. Chauhan, K. Ishitsuka, S. Kumar, N. Raje, P. G. Richardson, J.-L. Harousseau, et al. VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosis Blood, November 1, 2004; 104(9): 2886 - 2892. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, C. Mitsiades, R. Schlossman, N. Munshi, P. Richardson, F. E. Cotter, and K. C. Anderson Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells Blood, October 15, 2004; 104(8): 2458 - 2466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, K. Podar, T. Hideshima, R. Shringarpure, L. Catley, C. Mitsiades, N. Munshi, Y. T. Tai, N. Suh, et al. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance Blood, April 15, 2004; 103(8): 3158 - 3166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hideshima, D. Chauhan, T. Hayashi, K. Podar, M. Akiyama, C. Mitsiades, N. MItsiades, B. Gong, L. Bonham, P. de Vries, et al. Antitumor Activity of Lysophosphatidic Acid Acyltransferase-{beta} Inhibitors, a Novel Class of Agents, in Multiple Myeloma Cancer Res., December 1, 2003; 63(23): 8428 - 8436. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, L. Catley, Y. T. Tai, T. Hayashi, R. Shringarpure, et al. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance Blood, November 1, 2003; 102(9): 3379 - 3386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, R. Shringarpure, K. Podar, Y. Ohtake, T. Hideshima, and K. C. Anderson Blockade of Hsp27 Overcomes Bortezomib/Proteasome Inhibitor PS-341 Resistance in Lymphoma Cells Cancer Res., October 1, 2003; 63(19): 6174 - 6177. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Sattler, L. R. Quinnan, Y. B. Pride, J. L. Gramlich, S. C. Chu, G. C. Even, S.-K. Kraeft, L. B. Chen, and R. Salgia 2-Methoxyestradiol alters cell motility, migration, and adhesion Blood, July 1, 2003; 102(1): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shimada, M. Nakamura, E. Ishida, M. Kishi, and N. Konishi Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis Carcinogenesis, June 1, 2003; 24(6): 1067 - 1075. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Chauhan, G. Li, T. Hideshima, K. Podar, C. Mitsiades, N. Mitsiades, N. Munshi, S. Kharbanda, and K. C. Anderson JNK-dependent Release of Mitochondrial Protein, Smac, during Apoptosis in Multiple Myeloma (MM) Cells J. Biol. Chem., May 9, 2003; 278(20): 17593 - 17596. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Chauhan, G. Li, D. Auclair, T. Hideshima, P. Richardson, K. Podar, N. Mitsiades, C. Mitsiades, C. Li, R. S. Kim, et al. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays Blood, May 1, 2003; 101(9): 3606 - 3614. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
; RPMI-8226, 
; LR-5, 
; Dox-6, 
;
Dox-40, 
; MM.1R,
) with the
indicated doses of 2ME2 for 72 hours. Results are mean ± SD from
5 independent experiments; P < .0001 for all cell lines.
(C) Effect of treatment with 2ME2 (0-20 µM) for 72 hours on normal
lymphocyte viability, assessed by MTT assay. Results are the mean ± SD of 5 independent experiments; P = 0.23 from J-T test
for trend. (D) MM cells (CD138+) from 5 patients (patients 1-5) were
treated with 2ME2 (9 µM) for 72 hours, followed by BrdU assay. Values
are the mean ± SD of triplicate samples (P = .06);
experiments were repeated 3 times with similar results. (E) 2ME2
induces proteolytic cleavage of PARP in patient MM cells. CD138+ cell
from 2 MM patients and normal lymphocytes from 2 healthy donors were
treated with 2ME2 (9 µM) for 72 hours and harvested, and total
protein lysates were subjected to SDS-PAGE analysis. Immunoblot
analysis of the lysates was performed with anti-PARP antibody. FL
indicates full length; CF, cleaved fragment.
.